Search for Clinical Trial Results

Sponsored By

Glomerulosclerosis, Focal Segmental - 25 Studies Found

Status Study
Completed Study Name: A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Condition: Glomerulosclerosis, Focal Segmental
Date: 2013-11-27
Interventions: Drug: Losmapimod Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round,
Completed Study Name: Sirolimus for Focal Segmental Glomerulosclerosis
Condition: Focal Glomerulosclerosis
Date: 2002-06-26
Interventions: Drug: Sirolimus
Terminated Study Name: Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
Condition: Focal Segmental Glomerulosclerosis
Date: 2008-10-27
Interventions: Drug: FG-3019 FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
Terminated Study Name: Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis
Date: 2009-08-10
Interventions:
  • Drug: prednisone, FK506, MMF 1
Completed Study Name: Permeability Factor in Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis
Date: 2000-12-22
Interventions:
  • Procedure: Plasma exchange A c
Recruiting Study Name: Genetic Markers for Focal Segmental Glomerulosclerosis
Condition:
  • Focal Segmental Glomerulosclerosis
  • HIV-Associated Focal Segmental Glomerulosclerosis
    Date: 2008-12-31
    Interventions: Drug: Galactose Oral galactose, 0.2 g/kg/dose twice daily for 28 days
Recruiting Study Name: Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis
Condition:
  • Glomerulosclerosis, Focal Segmental
  • Renal Insufficiency, Chroni
    Date: 2016-01-30
    Interventions: Biological: Autologous Cell Transplantation Endovascular infusion of bone marrow derived cells in both r
Completed Study Name: Rituximab Treatment of Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis (FSGS)
Date: 2007-10-26
Interventions: Drug: rituximab 375 mg/m2 intravenously for 4 doses
Active, not recruiting Study Name: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis
Date: 2012-06-04
Interventions:
  • Drug: RE-021 (Sparsentan) Oral
Next >>>